Credit: Getty Images Determining the presence or absence of gene mutations associated with aggressive prostate cancer can have implications for risk stratification, monitoring, and therapy. Genetic ...
A minority of patients with metastatic castration-resistant prostate cancer (mCRPC) in the United States undergo genetic testing for homologous recombination repair (HRR) mutations, despite the ...
Credit: Getty Images In the US, the proportion of men receiving HRR testing peaked at 55.5% in 2020 and decreased to 49.4% in 2022. From 2014-2022, only about 38% of men with metastatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback